In an in vitro study, these two types of EGFR mutants demonstrated an enhanced TK activity in response to EGF and increased sensitivity to inhibition by TKI, although the biological activity between tumours with L858R and those with deletions was different (Paez et al, 2004; Pao et al, 2004). The gene discussed is EGFR; the disease is neoplasm.